Published On: Dec 15, 2023
Last Updated On: Jul 10, 2024
Today the eczema community is one step closer to having a new treatment option. The U.S. Food and Drug Administration (FDA) has approved Zoryve cream (roflumilast 0.15%) from manufacturer Arcutis Biotherapeutics, for the treatment of mild to moderate atopic dermatitis in adults and children ages 6 and older.
Zoryve is also available as a foam (0.3%) for the treatment of seborrheic dermatitis in patients 9 years of age and older. Zoryve foam (0.3%) was approved by the FDA in December 2023.
Zoryve is a once-daily topical, which can be used anywhere on the body for any duration. Zoryve is not a topical steroid. Zoryve inhibits the enzyme phosphodiesterase-4 (PDE4), which is involved in the production of pro-inflammatory mediators and this action reduces inflammation in dermatological conditions.
It’s important to talk to your doctor about how atopic dermatitis or seborrheic dermatitis affects your skin and other aspects of your life. Together, you and your healthcare provider can determine if Zoryve is an appropriate treatment option.
Learn more about Zoryve and other new prescription treatments on our website.
The U.S. Food and Drug Administration has approved Ebglyss (lebrikizumab-lbkz) from manufacturer Eli Lilly and Company for the treatment of moderate-to-severe atopic dermatitis for use by adults and children 12 years of age and older.
Cibinqo (abrocitinib) has been approved by the U.S. Food and Drug Administration (FDA). Cibinqo, from manufacturer Pfizer, will be available by prescription only.
Today the eczema community is one step closer to having a new treatment option. Adbry™ (tralokinumab-ldrm), a biologic medication for adults (18+) with moderate to severe atopic dermatitis (AD) for whom topical prescription treatments have not adequately worked or are not advised, has been approved by the U.S. Food and Drug Administration (FDA).
Evidence-based articles, expert-sourced lifestyle tips and stories from your community.